medigraphic.com
ISSN 0016-3813 (Print)

2017, Number 4

<< Back

Gac Med Mex 2017; 153 (4)

Trombosis venosa esplácnica como manifestación inicial de mielofibrosis primaria

Campos-Cabrera G, Campos-Cabrera V, Campos-Cabrera S, Campos-Villagómez JL, Romero-González A

Language: Spanish
References: 18
Page: 537-540
PDF size: 124.12 Kb.


ABSTRACT

Myeloproliferative neoplasms are chronic disorders of clonal hematopoietic stem cells, characterized by an overproduction of functional granulocytes, red blood cells and / or platelets, and one of the major complications is the occurrence of venous and arterial thrombotic problems caused by increased platelet aggregation and thrombin generation. In this study 11 cases of primary myelofibrosis (PM) were evaluated and 2 debuted with splanchnic venous thrombosis (SVT); so after seeing the results of this study and of world literature, it is suggested that in patients with SVT, diagnostic methods for PM like the JAK2V617F mutation should be included.


REFERENCES

  1. Tripodi A, Primignani M, Lemma L, et al. Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. J Hepatol. 2013;59:265-70.

  2. Vargas-Viveros P, Hurtado-Monroy R, Candelaria-Hernández MG. Mejoría en la calidad de vida y respuesta sintomática en pacientes con mielofibrosis primaria, mielofibrosis post-policitemia vera y mielofibrosis post-trombocitemia esencial tratados con el inhibidor de JaK-1 y JaK-2 ruxolitinib. Med Int Mex. 2013;29:363-9.

  3. Landolfi R, Di GL, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia. 2008;22:2020-8.

  4. Sekhar M, McVinnie K, Burroughs AK. Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol. 2013;162:730-47.

  5. Castro Ríos M, Heller P, Kornblihtt L, et al. Neoplasias mieloproliferativas crónicas clásicas BCR-ABL negativas. Buenos Aires: Sociedad Argentina de Hematología; 2012. p. 317-62.

  6. Chait Y, Condat B, Cazals-Hatem D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol. 2005;129:553-60.

  7. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-61.

  8. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol. 2016;64:179-202.

  9. Kreher S. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). Ann Hematol. 2014;93:1953-63.

  10. Link CS, Platzbecker U, Kroschinsky F, et al. Association of oesophageal varices and splanchnic vein thromboses in patients with JAK2-positive myeloproliferative neoplasms: presentation of two cases and data from a retrospective analysis. Cas Rep Oncol. 2013;6:311-5.

  11. Van der Heijden JF, Hutten BA, Buller HR, et al. Vitamin K antagonists or low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev. 2002;(1):CD002001.

  12. Chagneau-Derrode C, Roy L, Guilhot J, et al. Impact of cytoreductive therapy on the outcome of patients with myeloproliferative neoplasms and hepatosplanchnic vein thrombosis. J Hepatol. 2013;58:857.

  13. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010; 115:3109-17.

  14. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787-98.

  15. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363:1117-27.

  16. Shi JG, Chen X, McGee RF, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 2011;51:1644-54.

  17. O’Sullivan JM, McLornan DP, Harrison CN. Safety considerations when treating myelofibrosis. Expert Opin Drug Saf. 2016 Sep;15(9):1185-92.

  18. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based in a study of The International Working Group for Myelofibrosis Research and Treatment. Blood. 2009; 113:2895-901.




2020     |     www.medigraphic.com